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Abstract
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Background—Cannabidiol (CBD) is a naturally occurring constituent of the marijuana plant. In
the past few years, there has been great interest in the therapeutic effects of isolated CBD and it is
currently being explored for numerous disease conditions (e.g., pain, epilepsy, cancer, various drug
dependencies). However, CBD remains a Schedule I drug on the U.S. Controlled Substances Act
(CSA). Despite its status, there are no well-controlled data available regarding its abuse liability.
Methods—Healthy, frequent marijuana users (n=31) were enrolled in this within subject,
randomized, placebo-controlled, double-blind, multisite study that administered oral cannabidiol
(0, 200, 400, 800 mg) alone and in combination with smoked marijuana (0.01%, 5.3-5.8% THC).
Participants received one dose combination across 8 once-weekly outpatient sessions (7.5 hrs).
The primary findings on the drug interaction effects were previously reported (Haney et al., 2016).
The present study is a secondary analysis of the data to examine the abuse liability profile of oral
cannabidiol (200, 400, 800 mg) in comparison to oral placebo and active smoked marijuana
(5.3-5.8% THC).
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Results—Active marijuana reliably produced abuse-related subjective effects (e.g., high) (p<.05).
However, CBD was placebo-like on all measures collected (p>.05).
Conclusions—Overall, CBD did not display any signals of abuse liability at the doses tested and
these data may help inform U.S. regulatory decisions regarding CBD schedule on the CSA.
Keywords
Cannabidiol; CBD; abuse liability; smoked marijuana; human
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1. Introduction
Cannabidiol (CBD) and delta-9-tetrahydracannabinol (THC) are two of the dozens of
naturally occurring chemicals present in the marijuana plant (e.g., cannabinoids). The
concentration of cannabinoids in marijuana varies considerably depending on the strain and
plant breeding techniques. For example, confiscated marijuana in the United States and
Australia over the past decade has contained minimal concentrations of CBD (CBD: 0.14 –
0.17%) (Mehmedic et al., 2010; Swift et al., 2013); however, strains with high
concentrations of both THC and CBD (4.5 – 9.3% CBD) are emerging (Freeman et al.,
2014).
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Although the mechanism of action of THC has been well documented, the action of CBD on
the cannabinoid receptor system is unclear. There is little to no direct activity at CB1 or CB2
receptors (Pertwee, 2010); however, there are data suggesting that CBD may increase
endocannabinoid tone by inhibiting fatty acid amide hydrolase (FAAH), an enzyme that
degrades the endogenous cannabinoid, anandamide (Bisogno et al., 2001; de Petrocellis et
al., 2011). Outside of the cannabinoid system, CBD modulates glycine, adenosine, TRPV1,
GPR55, and acts as a 5HT1A agonist (Pertwee et al., 2008; 2010). CBD has also been
demonstrated to have antioxidant, anti-inflammatory, neuroprotectant and analgesic effects
in preclinical models (Hampson et al., 1998; Maione et al., 2011).
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Clinically, CBD is available in several countries (e.g., Israel, England) for therapeutic use
and is available on the international market (e.g., Canada, Spain) as a combination product
of equal concentrations of CBD and THC (Sativex®) for the treatment of multiple sclerosis
spasticity. There are also several single entity CBD products (e.g., Epidiolex®, Arvisol®) in
development and under investigation in clinical trials for several disease conditions (e.g.,
epilepsy, schizophrenia, diabetes, drug dependence); some of these trials have issued reports
on the safety of CBD, but data on the efficacy of these products are not yet available. There
are also unregulated, non-pharmaceutical products, such as strains of high-CBD marijuana
processed to produce oil, that are being used to treat various illnesses – these preparations
have not been studied in clinical trials for safety or efficacy and their chemical constituents
are largely unknown (with some products containing little to no CBD [FDA Warning Letter,
2015]). One U.S. trial is underway to examine the genetic differences between patients with
Dravet syndrome (i.e., intractable epilepsy) who are responders and non-responders to nonpharmaceutical CBD oil (NCT02229032).

Author Manuscript

Despite the significant interest and increasing use of these products, there are no wellcontrolled published studies that have examined the abuse liability of CBD. Several studies
have administered oral doses (≤600 mg) of CBD to healthy participants with little to no
marijuana use histories and have reported minimal side effects (Bergamaschi et al., 2011;
Bhattacharyya et al., 2010; Cunha et al., 1980; Hollister, 1973; Karniol et al., 1974; Zuardi
et al., 1993). Oral CBD has been tested in clinical populations (Huntington's disease,
epilepsy patients) at much higher cumulative doses (e.g., 1280 mg/day; 50 mg/kg/day) with
reports of somnolence, decreased appetite/weight loss, diarrhea and increased seizure in a
small subset of epilepsy patients (Consroe et al., 1991; Devinsky et al., 2016; Tzadok et al.,
2016). Despite the frequent statements in the media and the scientific literature that CBD is
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void of psychoactive effects, this has never been formally assessed – no studies have
completed an abuse liability assessment, enrolled the population of interest (marijuana users)
or compared CBD effects to a cannabinoid agent with known abuse liability, such as smoked
marijuana, as a positive control.
The current study is a secondary analysis of a trial that examined a wide range of oral CBD
doses alone and in combination with smoked marijuana and reported that CBD does not
alter the subjective, physiological or reinforcing effects of marijuana (see Haney et al.
(2016) for detailed methods). The current analyses focus on the abuse liability of a range of
oral CBD doses (up to 800 mg) compared to oral placebo (negative control) and smoked
marijuana (positive control) in a sample of heavy marijuana smokers.

2. Methods
Author Manuscript

2.1 Participants
Participants were healthy marijuana smokers who completed in-person screening evaluations
that included medical history, physical exam, psychiatric assessments, urinalysis, blood
chemistry, and 12-lead ECG. Inclusion criteria included self-report of smoking marijuana at
least 4 times per week over the past 4 weeks (half of a joint equivalent on each occasion) and
an observed THC-positive urine sample. Exclusion criteria included physiological drug
dependence requiring medical care (benzodiazepine, alcohol dependence), pregnancy, and
serious medical (e.g., diabetes) or psychiatric (e.g., suicidality) problems (see Haney et al.,
2016 for full inclusion/exclusion criteria).
2.2 Drugs
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The study was conducted under an Investigational Drug Application from the Food and
Drug Administration (113,221). Oral CBD doses (pure synthetic (-)-CBD, STI
Pharmaceuticals, Essex, England; packaged by Eminent Services Corp., Frederick,
Maryland; size 00 capsules) were prepared in blinded packaging by the investigational
pharmacy at each site. Marijuana cigarettes (inactive: 0.01% THC, 0.001% CBD; active:
5.3%-5.8% THC, 0.01% CBD) were provided by Research Triangle Institute (RTI).
2.3 Study Design
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This was a three-site, 8-week randomized, within-subject, double blind, placebo-controlled
outpatient study conducted at Columbia University, the Medical University of South
Carolina and the University of Kentucky. Each participant completed a total of 8 sessions
(7.5 hrs) and received one dose combination of oral CBD (0, 200, 400, 800 mg) and smoked
marijuana (0.01, 5.3%-5.8% THC) during each session. There was a minimum of 1-week
washout between sessions to preclude potential CBD carry-over effects.
This study was approved by the Institutional Review Boards at each university and was
conducted in accordance with the Helsinki guidelines for ethical research. All participants
provided sober, written informed consent prior to study participation and were paid for their
participation.
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2.4 Physiological Assessments
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Heart rate and blood pressure were collected prior to (baseline) and at regular intervals after
CBD administration (0.5, 1, 1.4, 1.75, 2, 2.5, 3, 3.5, 4, 4.7, 5.2, 5.7, 6.67 hrs – designed to
capture the time-action effects of both oral CBD and smoked marijuana).
2.5 Performance Measures
Two performance measures, a Digit Symbol Substitution Task (DSST) and a Continuous
Performance Task (CPT) were assessed. The DSST is a psychomotor task that assesses
speed and accuracy of pattern recognition (3 minute task) and the CPT measures sustained
selective attention (5 minute task).
2.6 Participant-Rated Measures
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Visual analog measures were collected before and at regular intervals after drug
administration. Participants rated their responses on a 100 mm line, anchored with “not at
all” (0 mm) to “extremely” (100 mm). Measures included ratings of marijuana drug effects
(e.g., street value, drug liking) and a 44-item mood inventory (e.g., high, good drug effects,
sedated, alert, hunger), with selected measures having demonstrated sensitivity to
cannabinoid agonists (Haney et al., 2004, Lile et al., 2010).
2.6 Statistical Analysis
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All measures were initially analyzed as raw time course data using a three-factor repeated
measures model (marijuana dose, CBD dose, time). Peak/trough scores were analyzed using
a one-factor model (dose). Tukey's post-hoc tests examined the time course of the drug
effects, individual doses compared to oral placebo, and differences between the comparator
dose conditions (e.g., active marijuana/placebo CBD condition compared to cannabidiol [0,
200, 400, 800 mg]/inactive marijuana conditions). All models were conducted with Proc
Mixed in SAS 9.3 (Cary, NC) with significance at p < 0.05.

3. Results
A total of 31 participants completed the study across the three study sites: 14 women, 17
men; mean age (± SEM) was 29.1 ± 1.7 years (range: 19 - 49 years). Participants reported
smoking marijuana 6.5 ± 0.2 days per week and lifetime regular use of 9.3 ± 1.2 years
(range: 0.5 – 29 years); 18 participants were cigarette smokers, 13 were non-smokers. CBD
was well tolerated and there were no serious adverse events related to the study medications.
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Figure 1 presents peak ratings of the VAS items “I feel high” and “I feel a good drug effect”
and a marijuana street value assessment across the five test conditions. In each of the VAS
measures displayed (first two panels), active marijuana produced increases in ratings (p<.
05), with peak ratings ranging from 52 – 56 (out of a maximum of 100) across the measures.
In contrast, the active doses of CBD produced minimal effects that were comparable to those
of the placebo/inactive marijuana condition (ratings in the range of 11 – 18) (p>0.05).
Placebo CBD and all active doses of CBD produced lower ratings than the active marijuana
condition (p<0.05; Table 1). Similar results were obtained for several other measures of drug
effect, including ratings of sedated and mellow, with active marijuana increasing ratings
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while CBD doses were placebo-like (p<0.05; see Table 1). The far right panel of Figure 1
displays street value estimates, with similar results – the active marijuana dose produced
peak street value estimates of $7.50 (p<0.05), while active CBD doses ($3.21 – $4.09) and
the placebo/inactive marijuana condition ($3.33) produced comparable ratings (p>0.05).
Neither active marijuana nor any dose of active CBD changed performance on the DSST or
CPT (p>.05).
Active marijuana produced increases in peak heart rate (p<.05; Table 1), while CBD was
placebo-like on heart rate and blood pressure measures (p>.05).
Overall, across all the multitude of measures collected, there were no significant effects of
CBD detected on peak or time course outcomes (p>.05).
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4. Discussion
This study enrolled healthy frequent marijuana users and explored the relative abuse liability
of a wide dose range of oral CBD in comparison to placebo (0.01% THC) and smoked
marijuana (5.3%-5.8% THC). Active smoked marijuana reliably produced increases in
measures of abuse liability, including ratings of high, like drug effect, drug strength, willing
to take again, and mellow. These findings are consistent with a large number of studies that
have administered similar doses to marijuana smokers and reported increases in abuserelated subjective measures (e.g., Cooper et al., 2009; 2010; Hart et al., 2002).
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The physiological, behavioral and abuse-related subjective effects of a wide range of doses
of CBD (200, 400, 800 mg) were also assessed. In contrast to smoked marijuana, CBD did
not produce increases in any subjective ratings of drug effect (relative to placebo CBD).
Specifically, CBD was placebo-like on all measures collected, including street value
estimates and ratings of high, feeling good drug effect, desire to take again, sedated and
mellow (Table 1). This lack of detectable effects does not appear to be due to a low dose
range or poor bioavailability. The dose range tested is higher than the doses tested (i.e., 600
mg) in a study that reported some attenuation of the psychotropic effects of THC
(Bhattacharyya et al., 2010). Also, the highest dose tested (800 mg dose) appears to be the
highest acute oral dose administered to healthy participants (although cumulative daily doses
in clinical populations can exceed 1500 mg/day). We previously reported (Haney et al.,
2016) that the 800 mg dose was readily absorbed and produced increases in plasma
concentrations after administration (Cmax = 77.9 ±25 ng/mL, Tmax=180 minutes). Overall,
these data indicate that CBD, even at very high doses, does not produce any detectable
effects in a sample of marijuana smokers and does not display signals of abuse liability.
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The ratings of the inactive marijuana/placebo CBD condition for the VAS and street value
assessment were slightly elevated (e.g., approximately 10-20/100 on VAS; approximately $3
street value), indicating a small placebo response. These placebo ratings were similar to
those observed after active CBD dose administration (p >.05). These ratings may be due to
the placebo marijuana (designed to smell and taste similar to active marijuana) that was
administered with each of these oral doses. Other studies have reported a similar placebo
response in marijuana smokers (Cooper and Haney, 2009; Hart et al., 2002).
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This study enrolled heavy marijuana smokers, as they have experience with cannabinoids,
and are the appropriate population to test both the efficacy and abuse liability of new
cannabinoid medications. However, it is possible that this population was tolerant to the
cannabinoid effects produced by CBD and may not be sensitive even to the high dose of
CBD tested. It is possible that a higher dose may be necessary to produce measurable effects
in this population. Although this is possible, it is unlikely due to the relatively low CBD
levels present in many marijuana strains in the U.S. and abroad (<0.2% CBD) (ElSohly et
al., 2014; Swift et al., 2013). In addition, the subset of participants (n=8) who completed a
pharmacokinetic assessment all had circulating CBD levels that were below the limit of
quantification (<0.25 ng/mL) in their plasma prior to CBD administration (Haney et al.,
2016), similar to other studies of frequent marijuana smokers (Desrosiers et al., 2014). THC
cross-tolerance may also be unlikely because of the unique pharmacological profile of CBD.
Although CBD appears to inhibit FAAH and increase anandamide availability, it is an
atypical cannabinoid that has action at multiple receptor systems, including 5HT1A, glycine
α1, α3, TRPV1, and GPR55. CBD also appears to be an allosteric modulator of mu- and
delta-opioid receptors, voltage-gated sodium channels and inhibit cyclooxygenase (COX)
(Kathmann et al., 2006; Patel et al., 2008; for review see Pertwee, 2008). Further, previous
studies have administered CBD to normal healthy participants with little to no marijuana use
history and have reported very mild or no changes in subjective ratings. Two studies have
reported mild anxiolytic effects of 300 and 600 mg CBD (Bergamaschi et al., 2011; Zuardi
et al., 1993) when administered prior to an experimental anxiety task. However, other studies
have reported no changes in any subjective effects, qualitative self reports or assessments
after administration of acute oral ([15, 30, 60 mg] Karniol et al., 1974; [20-100 mg],
Hollister, 1973; [600 mg] Bhattacharyya et al., 2010), chronic oral ([3 mg/kg/day for up to
30 days] Cunha et al., 1980), smoked (150 μg/kg, Dalton et al., 1976), or intravenous ([5-30
mg] Hollister, 1973) CBD doses.

Author Manuscript

Overall, there is substantial interest in the potential therapeutic effects of CBD, and it is
being explored for the treatment of diverse disease conditions (over 25 conditions under
investigation, as listed on clinicaltrials.gov). CBD products are available in several countries;
however, CBD is currently classified as a Schedule I drug in the United States, which is
defined as 1) an agent with high potential for abuse, 2) no currently accepted medical use,
and 3) lack of accepted safety information (U.S. Controlled Substances Act, 21 U.S.C.
§812). This study addresses the first criterion, as the data indicate that CBD has low
potential for abuse; however, it currently remains unclear if CBD is safe for long-term use or
clinically useful for the treatment of any of the disease conditions currently under
investigation. However, this study may help inform U.S. regulatory decisions if CBD shows
medicinal promise in clinical trials.
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Peak ratings of the visual analog items “I feel high” (left panel) and “I feel a good drug
effect” (middle panel) and estimates from a marijuana street value assessment (right panel)
presented as a function of dose condition (n=31, ±SEM). Peak effect analyses detected a
main effect of active marijuana (5.3-5.8% THC) on each measure. Tukey's post-hoc tests
indicated that 1) active CBD doses were not significantly different from placebo CBD (p>.
05) and 2) active marijuana condition was significantly different from each of the CBD dose
conditions (0, 200, 400, 800 mg, collected under inactive marijuana [0.01% THC]
conditions), as indicated by the asterisk (p<.05). The abbreviations on the graphs are as
follows: MJ=active marijuana/placebo CBD, CBD 0= 0 mg CBD/placebo marijuana, CBD
200 = 200 mg CBD/placebo marijuana, CBD 400 = 400 mg CBD/placebo marijuana, CBD
800 = 800 mg CBD/placebo marijuana.
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All measures were analyzed as peak maximum score. Values are mean peak scores and standard error of the mean (displayed in parentheses) for active marijuana (5.3-5.8% THC), placebo (0 mg CBD/
inactive marijuana) and each of the cannabidiol conditions: 200, 400, 800 mg CBD (collected under inactive marijuana conditions [0.01% THC]). All measures displayed a main effect of dose (p<.05) and F
values are reported. Tukey post-hoc tests were conducted; bolded values indicate the mean is significantly different from the active marijuana condition (p<.05). All means in the active CBD conditions
(CBD 200, 400, 800) were placebo-like (p>0.5). All means in the active marijuana condition are significantly different from placebo (p<.05), except for blurred vision and sounds are louder than usual
(p>0.5).
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